Stock Groups

Incyte Earnings, Revenue Beat in Q3 -Breaking

by Mike Robinson

[ad_1]

© Reuters. Incyte Revenue Beats in Q3

Investing.com – Incyte (NASDAQ) reported Tuesday that the third quarter beat analyst forecasts with revenue surpassing expectations.

Incyte reported earnings per share at $0.82 on revenues of $813M. Investing.com polled analysts and predicted EPS at $0.574 for revenue $739.09M.

Incyte shares have fallen 2% since the start of the year. However, they are still 31.65% below their 52-week high of $101.47 on January 25. The Nasdaq is currently up 21.01% since the beginning of the year, but they are still below Incyte shares.

Incyte is following other notable earnings from the Healthcare sector this month

Incyte’s report follows an earnings beat by J&J on October 19, who reported EPS of $2.6 on revenue of $23.34B, compared to forecasts EPS of $2.35 on revenue of $23.64B.

Thermo Fisher Scientific’s third quarter earnings per share (EPS) was $5.76 on $9.33B in revenue, beating expectations. The forecast for an EPS of $4.68 on $8.38B revenue was incorrect.

You can keep up to date on the latest earnings reports at www.investors.com Investing.com’s earnings calendar

Disclaimer Fusion MediaThis website does not provide accurate and current data. CFDs are stocks, indexes or futures. The prices of Forex and CFDs are not supplied by exchanges. They are instead provided by market makers. As such, the prices might not reflect market values and could be incorrect. Fusion Media is not responsible for trading losses that may be incurred as a consequence of the use of this data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.



[ad_2]